Skip to main content

Table 3 Benefits and harms of the HPV vaccines: characteristics of included participants

From: Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports

Characteristics of included participantsaTotalHPV vaccineComparator
HPV vaccine
(N = 47,075)
Comparator
(N = 48,595)
Cervarix
(N = 31,316)
Gardasil
(N = 13,937)
Gardasil 9
(N = 618)
HPV 16 vaccine
(N = 1204)
Placebo
(N = 306)
Adjuvantb
(N = 18,789)
Hepatitis vaccinec
(N = 29,500)
Participation
 Randomised47,07548,59531,31613,937618120430618,78929,500
  Received one (1) dose47,012 (99%)48,556 (99%)31,291 (99%)13,927 (99%)615 (99%)1193 (99%)306 (100%)18,750 (99%)29,500 (100%)
  Received two (2) doses46,105 (98%)47,725 (98%)30,788 (98%)13,564 (97%)604 (98%)1092 (91%)304 (99%)18,304 (97%)29,117 (99%)
  Received three (3) doses45,079 (96%)46,726 (96%)30,073 (96%)13,286 (95%)597 (97%)1019 (85%)300 (98%)17,906 (96%)28,520 (97%)
  Completed vaccination period44,202 (94%)45,862 (94%)29,331 (94%)13,156 (94%)595 (97%)993 (82%)300 (98%)17,809 (95%)27,753 (94%)
  Entered follow-up period18,540 (39%)18,059 (37%)4090 (14%)13,344 (96%)Not applicable1126 (94%)Not applicable17,590 (94%)469 (2%)
  Completed follow-up period15,826 (34%)14,601 (30%)2929 (10%)11,986 (86%)Not applicable835 (69%)Not applicable14,445 (77%)156 (1%)
Gender
 Female42,036 (89%)37,066 (76%)28,876 (92%)11,338 (81%)618 (100%)1204 (100%)306 (100%)16,481 (88%)20,279 (69%)
Age
 Mean age in years20.320.221.221.419.020.019.022.920.5
 Age group range in years9–728–689–729–4512–2616–2512–269–688–46
Race
 Asian7589 (16%)7295 (15%)6232 (20%)1248 (9%)40 (6%)69 (6%)14 (5%)2678 (14%)4603 (16%)
 Black1426 (3%)1492 (3%)467 (2%)862 (6%)3 (1%)94 (8%)3 (1%)1108 (6%)381 (1%)
 Hispanic4492 (10%)4378 (9%)1787 (6%)2616 (19%)0 (0%)89 (7%)0 (0%)3403 (18%)975 (3%)
 White31,743 (67%)33,558 (69%)22,335 (70%)7998 (56%)483 (78%)918 (76%)231 (75%)9960 (53%)23,367 (79%)
 Other1625 (3%)1576 (3%)297 (1%)1202 (9%)92 (15%)34 (3%)58 (19%)1343 (7%)174 (1%)
 Unknown209 (1%)296 (1%)198 (1%)11 (1%)0 (0%)0 (0%)0 (0%)297 (2%)0 (0%)
  1. aSee Additional file 2 for details on the characteristics of included participants. Table 3 does not include data from the two follow-up studies HPV-023 (follow-up for trial HPV-001) of 433 participants and HPV-063 (follow-up for trial HPV-032) of 752 participants
  2. bAdjuvant comparators included amorphous aluminium hydroxyphosphate sulphate (AAHS), aluminium hydroxide (Al[OH]3) and Gardasil’s carrier solution (yeast protein, sodium chloride, L-histidine, polysorbate 80 and sodium borate)
  3. cHepatitis vaccines included Aimmugen™ (hepatitis A vaccine), Engerix-B™ (hepatitis B vaccine), Havrix™ (hepatitis A vaccine) and Twinrix Paediatric™ (hepatitis A and B vaccine); see Additional file 2